• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Bellerophon plunges on failed cardiac implant trial

July 27, 2015 By Brad Perriello

Bellerophon TherapeuticsBellerophon Therapeutics (NSDQ:BLPH) said today that its bioabsorbable cardiac matrix failed to meet both the primary and secondary endpoints in a 303-patient clinical trial, sending its share price down nearly -63% today.

BCM is a liquid medical device injected into the coronary artery leading to the damaged area of a heart, and is designed for use after a heart attack. It forms a gel/scaffold in the damaged portion of the heart’s left ventricle and helps support the heart wall, to prevent further damage as well as congestive heart failure, allowing the heart to heal. Once its job is done, the BCM absorbed into and then eliminated from the body.

Bellerophon licenses the technology from BioLineRx (NSDQ:BLRX), which saw its shares drop -16.0% to $1.78 apiece today as investors reacted to the news.

Bellerophon, which spun out from Ikaria with a $60 million initial public offering earlier this year, said top-line results from the Preservation I trial showed no statistically significant differences between patients treated with BCM and patients treated with a placebo and no significant difference in adverse event rates between the groups.

Safety data analyzed to date shows no significant difference in adverse event rates for patients in the BCM and placebo treatment groups.

“We are clearly disappointed with the top-line results from Preservation I and will continue to investigate the full data set over the next few weeks and to reassess further clinical development of BCM,” chairman & CEO Jonathan Peacock said in prepared remarks.

Bellerophon said it plans to present detailed results from Preservation I  at the European Society of Cardiology’s annual meeting in London Sept. 1.

BLPH shares were down -62.9% to $2.84 apiece today.

Filed Under: Clinical Trials, Drug-Device Combinations Tagged With: Bellerophon Therapeutics

IN CASE YOU MISSED IT

  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care
  • Insulet up on Q2 sales beat, raised full-year guidance
  • Aptar acquires Orbital dry powder inhaler license
  • Tandem sinks on Q2 misses, slashed sales guidance

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS